SJW Group First Quarter 2025 Earnings: Beats Expectations
Revenue: US$167.6m (up 12% from 1Q 2024).
Net income: US$16.6m (up 42% from 1Q 2024).
Profit margin: 9.9% (up from 7.8% in 1Q 2024). The increase in margin was driven by higher revenue.
EPS: US$0.49 (up from US$0.36 in 1Q 2024).
AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Revenue exceeded analyst estimates by 4.4%. Earnings per share (EPS) also surpassed analyst estimates by 35%.
Looking ahead, revenue is forecast to grow 4.1% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Water Utilities industry in the US.
Performance of the American Water Utilities industry.
The company's shares are up 2.8% from a week ago.
You should learn about the 2 warning signs we've spotted with SJW Group (including 1 which is potentially serious).
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 minutes ago
- Yahoo
Mesoblast (ASX:MSB) Gains 15% In One Week With US FDA Orphan-Drug Approval
Mesoblast experienced a 15% increase in its share price over the past week, largely driven by a significant orphan-drug approval by the U.S. FDA for Ryoncil. This approval, granting seven years of exclusivity for a vital treatment, likely bolstered investor confidence given the strengthened competitive positioning of Mesoblast. While broader market trends saw the S&P 500 and Nasdaq reach new highs amid positive investor sentiment on U.S.-China trade discussions, Mesoblast's specific gains were more tied to its unique developments, as they provided a substantial boost, counterbalancing broader market movements. You should learn about the 1 warning sign we've spotted with Mesoblast. Explore 22 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research. Over the past three years, Mesoblast's total shareholder return, including share price changes and dividends, reached 181.00%. Despite recent gains driven by the U.S. FDA's orphan-drug approval for Ryoncil, the company's one-year performance outpaced the broader Australian Biotechs industry, which returned 12.3% less in the same timeframe. This highlights significant investor confidence and a positive reception to recent strategic advancements. While Mesoblast's share price has experienced impressive growth, it still trades at approximately 88% below consensus analyst price targets. The approval of Ryoncil positions the company competitively, potentially boosting future revenue, as evidenced by the expanded insurance coverage to 104 million U.S. lives. However, Mesoblast remains unprofitable, with A$47.93 million in net losses reported in its recent earnings. Analysts forecast substantial revenue growth at 56.7% annually, but profit forecasts show continued challenges for the next three years. The stock's recent appreciation reflects increased optimism, although the gap between the current share price and targeted fair value suggests room for further market adjustments. Our comprehensive valuation report raises the possibility that Mesoblast is priced lower than what may be justified by its financials. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ASX:MSB. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21 minutes ago
- Yahoo
Petro-Victory Energy Corp. Announces Short Term Loans
/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAWS/ DALLAS, June 11, 2025 /CNW/ - Petro-Victory Energy Corp. (TSXV: VRY) ("Petro-Victory" or the "Company") announces that it has borrowed an aggregate of US$350,000 (the "Loans") and issued unsecured promissory notes to Thomas Cooper, a director of the Company, and to an arm's length third party (collectively, the "Lenders"). The Loans have a term of one year and bear interest at an annual rate of 14% per annum until maturity and 18% per annum thereafter. The Lenders will be issued an aggregate of 685,350 bonus warrants (the "Warrants") in connection with the Loans, with each Warrant being exercisable at CAD$0.70 per common share on or before June 2, 2026. The Loans and issuance of Warrants remain subject to TSX Venture Exchange ("TSXV") final acceptance. The Loan from Thomas Cooper in the aggregate amount of US$175,000 and the issuance of 342,675 Warrants in connection therewith each constituted a "related party transaction" under Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101") as Mr. Copper is a related party (as defined in MI 61-101) of the Company. The Company relied on the exemptions from the formal valuation and minority shareholder approval requirements of MI 61-101 contained in Sections 5.5(a) and 5.7(1)(a) of MI 61-101 in respect of related party matters, as the Company is listed on the TSXV and neither the fair market value (as determined under MI 61-101) of the subject matter of, nor the fair market value of the consideration for, the transaction, insofar as it involves the related parties, exceeded 25% of the Company's market capitalization (as determined under MI 61-101). About Petro-Victory Energy Corp. Petro-Victory Energy Corp. is an oil and gas company engaged in the acquisition, development, and production of crude oil and natural gas in Brazil. The total portfolio under management includes 49 concession contracts with 276,755 acres, net to Petro-Victory plus an additional 6 concessions and 19,074 acres owned jointly with BlueOak. Through disciplined investments in high-impact, low-risk assets, Petro-Victory is focused on delivering sustainable shareholder value. The Company's common shares trade on the TSX Venture Exchange under the ticker symbol VRY. Cautionary Note Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities, in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws and may not be offered or sold within the United States unless an exemption from such registration is available. Advisory Regarding Forward-Looking Statements In the interest of providing Petro-Victory's shareholders and potential investors with information regarding Petro-Victory's future plans and operations, certain statements in this press release are "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 and "forward-looking information" within the meaning of applicable Canadian securities legislation (collectively, "forward-looking statements"). In some cases, forward-looking statements can be identified by terminology such as "anticipate," "believe," "continue," "could," "estimate," "expect," "forecast," "intend," "may," "objective," "ongoing," "outlook," "potential," "project," "plan," "should," "target," "would," "will" or similar words suggesting future outcomes, events or performance. The forward-looking statements contained in this press release speak only as of the date thereof and are expressly qualified by this cautionary statement. Specifically, this press release contains forward-looking statements relating to, but not limited to, TSXV approval for the Loan and Warrants. These forward-looking statements are based on certain key assumptions regarding, among other things, the receipt of TSXV approval for the Loan and Warrants. Readers are cautioned that such assumptions, although considered reasonable by Petro-Victory at the time of preparation, may prove to be incorrect. Actual results achieved will vary from the information provided herein as a result of numerous known and unknown risks and uncertainties and other factors. The above summary of assumptions and risks related to forward-looking statements in this press release has been provided in order to provide shareholders and potential investors with a more complete perspective on Petro-Victory's current and future operations and such information may not be appropriate for other purposes. There is no representation by Petro-Victory that actual results achieved will be the same in whole or in part as those referenced in the forward-looking statements and Petro-Victory does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by applicable securities law. SOURCE Petro-Victory Energy Corp. View original content to download multimedia:
Yahoo
32 minutes ago
- Yahoo
Serko Limited's (NZSE:SKO) Intrinsic Value Is Potentially 84% Above Its Share Price
Serko's estimated fair value is NZ$5.34 based on 2 Stage Free Cash Flow to Equity Serko's NZ$2.91 share price signals that it might be 46% undervalued Analyst price target for SKO is NZ$3.80 which is 29% below our fair value estimate Today we will run through one way of estimating the intrinsic value of Serko Limited (NZSE:SKO) by taking the forecast future cash flows of the company and discounting them back to today's value. One way to achieve this is by employing the Discounted Cash Flow (DCF) model. There's really not all that much to it, even though it might appear quite complex. Companies can be valued in a lot of ways, so we would point out that a DCF is not perfect for every situation. Anyone interested in learning a bit more about intrinsic value should have a read of the Simply Wall St analysis model. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. We're using the 2-stage growth model, which simply means we take in account two stages of company's growth. In the initial period the company may have a higher growth rate and the second stage is usually assumed to have a stable growth rate. To start off with, we need to estimate the next ten years of cash flows. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years. Generally we assume that a dollar today is more valuable than a dollar in the future, so we discount the value of these future cash flows to their estimated value in today's dollars: 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 Levered FCF (NZ$, Millions) -NZ$15.6m -NZ$8.50m NZ$900.0k NZ$10.4m NZ$17.3m NZ$25.6m NZ$34.4m NZ$43.0m NZ$51.0m NZ$58.2m Growth Rate Estimate Source Analyst x1 Analyst x2 Analyst x2 Analyst x1 Est @ 66.68% Est @ 47.69% Est @ 34.39% Est @ 25.08% Est @ 18.56% Est @ 14.00% Present Value (NZ$, Millions) Discounted @ 8.3% -NZ$14.4 -NZ$7.2 NZ$0.7 NZ$7.6 NZ$11.6 NZ$15.9 NZ$19.7 NZ$22.8 NZ$24.9 NZ$26.2 ("Est" = FCF growth rate estimated by Simply Wall St)Present Value of 10-year Cash Flow (PVCF) = NZ$108m We now need to calculate the Terminal Value, which accounts for all the future cash flows after this ten year period. The Gordon Growth formula is used to calculate Terminal Value at a future annual growth rate equal to the 5-year average of the 10-year government bond yield of 3.4%. We discount the terminal cash flows to today's value at a cost of equity of 8.3%. Terminal Value (TV)= FCF2034 × (1 + g) ÷ (r – g) = NZ$58m× (1 + 3.4%) ÷ (8.3%– 3.4%) = NZ$1.2b Present Value of Terminal Value (PVTV)= TV / (1 + r)10= NZ$1.2b÷ ( 1 + 8.3%)10= NZ$551m The total value is the sum of cash flows for the next ten years plus the discounted terminal value, which results in the Total Equity Value, which in this case is NZ$659m. In the final step we divide the equity value by the number of shares outstanding. Relative to the current share price of NZ$2.9, the company appears quite good value at a 46% discount to where the stock price trades currently. Remember though, that this is just an approximate valuation, and like any complex formula - garbage in, garbage out. Now the most important inputs to a discounted cash flow are the discount rate, and of course, the actual cash flows. If you don't agree with these result, have a go at the calculation yourself and play with the assumptions. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at Serko as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 8.3%, which is based on a levered beta of 1.137. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business. Check out our latest analysis for Serko Although the valuation of a company is important, it ideally won't be the sole piece of analysis you scrutinize for a company. DCF models are not the be-all and end-all of investment valuation. Preferably you'd apply different cases and assumptions and see how they would impact the company's valuation. If a company grows at a different rate, or if its cost of equity or risk free rate changes sharply, the output can look very different. What is the reason for the share price sitting below the intrinsic value? For Serko, there are three further aspects you should look at: Financial Health: Does SKO have a healthy balance sheet? Take a look at our free balance sheet analysis with six simple checks on key factors like leverage and risk. Future Earnings: How does SKO's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart. Other High Quality Alternatives: Do you like a good all-rounder? Explore our interactive list of high quality stocks to get an idea of what else is out there you may be missing! PS. The Simply Wall St app conducts a discounted cash flow valuation for every stock on the NZSE every day. If you want to find the calculation for other stocks just search here. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
